Suppression of Kynurenine 3-Monooxygenase as a Treatment for Triple-negative Breast Carcinoma
Laura A Sordillo1, Peter P Sordillo2
1The City College of New York, New York, NY, U.S.A.; LASORDILLO@gmail.com.
Abstract:
Kynurenine 3-monooxygenase (KMO), a key enzyme within the kynurenine (KYN) pathway of tryptophan (TRY) metabolism, enables the excess production of toxic metabolites (such as 3-hydroxykynurenine, xanthurenic acid, 3-hydroxyanthranilic acid and quinolinic acid), and modulates the balance between these toxic molecules and the protective metabolite, kynurenic acid (KYNA). Despite its importance, KMO suppression as a treatment for cancer has not been fully explored. Instead, researchers have focused on prevention of KYN pathway activity by inhibition of enzymes indoleamine 2,3-dioxygenase (IDO1 and IDO2) or tryptophan 2,3-dioxygenase (TDO, also known as TDO2). However, studies using IDO/TDO inhibitors against cancer have not yet shown that this type of treatment can be successful. We argue that KMO suppression can be an effective strategy for treatment of cancer by 1) decreasing toxic metabolites within the KYN pathway and 2) increasing levels of KYNA, which has important protective and anticancer properties. This strategy may be beneficial in the treatment of aggressive breast cancer, particularly in patients with triple-negative breast cancer. A major challenge to this strategy, when searching for an effective treatment for tumors, especially tumors like breast carcinoma that often metastasize to the brain, is finding KMO inhibitors that adequately cross the blood-brain barrier.
Insights
Kynurenine 3-monooxygenase (KMO) suppression may treat cancer by reducing toxic metabolites and increasing protective kynurenic acid (KYNA). This strategy shows promise for aggressive breast cancers, but requires blood-brain barrier-penetrating inhibitors.
Area of Science:
- Biochemistry
- Metabolic pathways
- Cancer biology
Background:
- The kynurenine (KYN) pathway of tryptophan metabolism involves Kynurenine 3-monooxygenase (KMO).
- KMO activity influences the balance between toxic KYN metabolites and the protective kynurenic acid (KYNA).
- Current cancer research focuses on inhibiting indoleamine 2,3-dioxygenase (IDO1/IDO2) or tryptophan 2,3-dioxygenase (TDO2), with limited success.
Purpose of the Study:
- To evaluate KMO suppression as a cancer treatment strategy.
- To explore the potential of targeting KMO for aggressive breast cancers, including triple-negative breast cancer.
- To identify challenges in developing KMO inhibitors for brain-metastatic cancers.
Main Methods:
- Review of existing literature on KYN pathway enzymes and cancer treatment.
- Analysis of the dual role of KMO in producing toxic metabolites and modulating KYNA levels.
- Discussion of therapeutic strategies involving KMO inhibition.
Main Results:
- KMO suppression can decrease harmful KYN metabolites.
- KMO suppression can increase beneficial KYNA levels, which possess anticancer properties.
- Targeting KMO may offer an alternative to IDO/TDO inhibition for cancer therapy.
Conclusions:
- KMO suppression presents a promising, yet underexplored, therapeutic strategy for cancer.
- This approach may be particularly effective against aggressive breast cancers.
- Developing KMO inhibitors that cross the blood-brain barrier is crucial for treating brain-metastatic tumors.
More Related Videos
08:19Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
13:38Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...